I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Sridhar Nimmagadda, Ph.D.
Associate Professor of Radiology and Radiological Science
Research Interests: Molecular imaging probes; chemokine receptors in cancer therapy and imaging; immune modulation therapies; non-invasive assessment of tumor response to therapy. ...read more
Sridhar Nimmagadda, Ph.D. is an Associate Professor of Radiology and Oncology, with joint appointments in Medicine, Clinical Pharmacology, and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine (JHU SOM). He serves as the Scientific Director of the Johns Hopkins Center for Translational Molecular Imaging, a center dedicated to clinical translation of molecular imaging agents.
Dr. Nimmagadda received a Master of Science degree in Chemistry from the Indian Institute of Technology, Madras and a Ph.D. in Cancer Biology in 2005 from Wayne State University/Karmanos Cancer Institute. Dr. Nimmagadda’s current research is focused on the development of novel imaging agents for chemokine receptors and immune cell related targets (PD-L1), and the application of those agents to quantify drug-target engagement at the tumor. This work is supported by NIH, DOD and several private foundations. He has authored 60 publications that focus on targeted imaging agent development and applying imaging techniques to characterize tumor biology.
- Associate Professor of Radiology and Radiological Science
- Associate Professor of Oncology
- Associate Professor of Pharmacology and Molecular Sciences
- Joint Appointment in Medicine
Departments / Divisions
Centers & Institutes
- B.Sc., Andhra Loyola College (India) (1994)
- Ph.D., Wayne State University School of Medicine (Detroit) (Michigan) (2005)
Molecular Imaging, Johns Hopkins University, Baltimore, MD, 2008, Postdoctoral Fellowship
Research & Publications
To understand tumor response to therapy, our laboratory works at the intersection of chemistry and biology, drawing on extensive expertise in chemical, radiochemical, and biocongugate -techniques, molecular imaging methodologies, and animal models. We synthesize imaging agents and therapeutics with a focus on cancer and immune -cell expressed proteins, including chemokine receptors (e.g., CXCR4) and the immune checkpoint proteins (e.g., PD-L1), and integrate those novel chemical tools with innovative imaging techniques to guide and optimize molecularly targeted combination therapies.
Technology Expertise KeywordsImaging, PET, SPECT, Radiopharmaceutical, Immunotherapy, Chemokine receptors
Selected PublicationsView all on Pubmed
Nimmagadda S, Pullambhatla M, Green G, Bhujwalla ZM, Pomper, MG., Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100-PET. Cancer Res, 70, 3935-3944, 2010.
De Silva RA, Peyre KP, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S., Imaging CXCR4 expression in human cancer xenografts: Evaluation of monocyclam [64Cu]AMD3465. J Nucl Med., 2011 Jun;52(6):986-93.
Chatterjee S, Lesniak W, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Behnam Azad B, Poper MG, Nimmagadda S. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016 Mar 1;7(9):10215-27
Lesniak W, Oskolkov N, Yang X, Pomper MG, Nimmagadda S*, McMahon MT*. Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI Nanoplatform. Nano Lett, 2016 Apr 13;16(4):2248-53.
Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7. PMID:30457978
Academic Affiliations & Courses
Graduate Program Affiliation
Pharmacology and Molecular Sciences
Activities & Honors